What drugs target Receptor tyrosine-protein kinase erbB-2?

9+ drugs target Receptor tyrosine-protein kinase erbB-2, including Enhertu, Kadcyla, Herceptin, Trastuzumab (Herceptin), Margenza.

What drug classes act on Receptor tyrosine-protein kinase erbB-2?

Drug classes acting on Receptor tyrosine-protein kinase erbB-2 include Antibody-drug conjugate, HER2/neu Receptor Antagonist [EPC], Kinase Inhibitor.

9 drugs 9 marketed

All drugs that target Receptor tyrosine-protein kinase erbB-2 — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Enhertu · Daiichi Sankyo · Oncology
Enhertu works by binding to the HER2 protein and releasing a cytotoxic payload to kill cancer cells.
Kadcyla · Roche · Antibody-drug conjugate · Oncology
Trastuzumab emtansine is a HER2-targeted antibody-drug conjugate that works by binding to the HER2 receptor and releasing a cytotoxic agent.
Herceptin · National Cancer Institute (NCI) · Oncology
Trastuzumab (Herceptin) · Pfizer Inc. · Oncology
Margenza · Macrogenics Inc · HER2/neu Receptor Antagonist [EPC] · Oncology
Margenza works by blocking the HER2/neu receptor, which is overexpressed in certain breast cancer cells, to prevent them from growing and multiplying.
Gleevec · Novartis · Kinase Inhibitor · Oncology
Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation.
Perjeta · BioRay Pharmaceutical Co., Ltd. · Oncology
Perjeta · Roche · HER2/neu Receptor Antagonist [EPC] · Oncology
Pertuzumab targets the extracellular dimerization domain of the HER2 protein, blocking ligand-dependent heterodimerization with other HER family members.
OGIVRI · MYLAN GMBH · HER2/neu Receptor Antagonist [EPC] · Oncology